In summary, we demonstrate that selective inhibition of NIK in vivo leads to inhibition of multiple pathways known to be involved in SLE, resulting in improvement of disease biomarkers, kidney function, and survival. This evidence concerns the gene MAP3K14 and systemic lupus erythematosus.